About aeglea bio therapeutics - SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
SYRE At a Glance
Spyre Therapeutics, Inc.
Building 23
Waltham, Massachusetts 02453
| Phone | 1-617-651-5940 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -149,555,000.00 | |
| Sector | Health Technology | Employees | 65 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SYRE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.875 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.105 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SYRE Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,300,846.154 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SYRE Liquidity
| Current Ratio | 11.256 |
| Quick Ratio | 11.256 |
| Cash Ratio | 11.156 |
SYRE Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -31.474 |
| Return on Equity | -42.619 |
| Return on Total Capital | -28.883 |
| Return on Invested Capital | -38.037 |
SYRE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |